The electrical pulse changes membrane permeability only temporarily, creating pores large enough for mRNA to cross before the membrane returns toward its prior barrier function. Once the RNA reaches the cytoplasm, it becomes available to ribosomes rather than needing entry into the nucleus. This separation between cytoplasmic translation and genomic DNA helps explain why the approach does not permanently modify the genome.
Natural degradation gives the system a temporary expression profile. The introduced RNA can produce the selected protein after cytoplasmic delivery, but it is not a permanent template for continued expression. This feature lets investigators test how cells respond to a chosen protein while limiting long-term genetic consequences, which is especially relevant when evaluating experimental immune-cell designs in cancer research.
Two intracellular processes determine the outcome after delivery. Ribosomes translate the cytoplasmic mRNA into the selected protein, creating the intended cellular program, while the RNA is naturally degraded afterward. Protein production therefore depends on successful cytoplasmic access and translation, whereas degradation prevents the introduced message from serving as a lasting source of expression.
In cancer research, investigators can deliver mRNA encoding tumor-associated antigens, receptors, or immune-modulating proteins into immune cells. The resulting protein expression provides a way to examine how those programmed cells participate in antitumor responses. This strategy also supports the development and testing of cell-based therapies without requiring a permanent change to the cells' genome.
A basic workflow begins by selecting mRNA for the protein under investigation, exposing cells to brief electrical pulses, and using the resulting membrane pores to enable cytoplasmic entry. Ribosomes then translate the delivered message into the selected protein. Researchers can use the resulting temporary protein production to evaluate a candidate design or cellular response.
The approach is useful when researchers need to test therapeutic designs rapidly and reversibly. Its nonviral delivery profile and temporary expression allow selected proteins to be evaluated in immune cells without committing the cells to permanent genetic alteration. That combination is suited to early studies of antitumor responses and to iterative development of cell-based therapy concepts.
A nonviral, transient format allows researchers to compare candidate antigens, receptors, or immune-modulating proteins while keeping expression temporary and avoiding permanent genomic changes. This can shorten the path from design to experimental testing because different protein programs can be evaluated in immune cells without establishing a lasting genetic modification. The resulting data can inform antitumor-response studies and cell-based therapy development.